Meanwhile GSK3β inhibitors are in clinical trials as a promising treatment against AD, and GSK3 inhibition has been shown to ameliorate Aβ pathology in animal models of AD (Sofola et al., 2010; del Ser et al., 2013; Georgievska et al., 2013; Prati et al., 2015). Here, GSK3B is linked to Alzheimer disease.